Literature DB >> 18990764

Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening.

Jenny N Poynter1, Kimberly D Siegmund, Daniel J Weisenberger, Tiffany I Long, Stephen N Thibodeau, Noralane Lindor, Joanne Young, Mark A Jenkins, John L Hopper, John A Baron, Dan Buchanan, Graham Casey, A Joan Levine, Loïc Le Marchand, Steven Gallinger, Bharati Bapat, John D Potter, Polly A Newcomb, Robert W Haile, Peter W Laird.   

Abstract

Microsatellite instability (MSI) occurs in 10% to 20% of colorectal cancers (CRC) and has been attributed to both MLH1 promoter hypermethylation and germline mutation in the mismatch repair (MMR) genes. We present results from a large population- and clinic-based study of MLH1 methylation, immunohistochemistry, and MMR germline mutations that enabled us to (a) estimate the prevalence of MMR germline mutations and MLH1 methylation among MSI-H cases and help us understand if all MSI-H CRC is explained by these mechanisms and (b) estimate the associations between MLH1 methylation and sex, age, and tumor location within the colon. MLH1 methylation was measured in 1,061 population-based and 172 clinic-based cases of CRC. Overall, we observed MLH1 methylation in 60% of population-based MSI-H cases and in 13% of clinic-based MSI-H cases. Within the population-based cases with MMR mutation screening and conclusive immunohistochemistry results, we identified a molecular event in MMR in 91% of MSI-H cases: 54% had MLH1 methylation, 14% had a germline mutation in a MMR gene, and 23% had immunohistochemistry evidence for loss of a MMR protein. We observed a striking age difference, with the prevalence of a MMR germline mutation more than 4-fold lower and the prevalence of MLH1 methylation more than 4-fold higher in cases diagnosed after the age of 50 years than in cases diagnosed before that age. We also determined that female sex is an independent predictor of MLH1 methylation within the MSI-H subgroup. These results reinforce the importance of distinguishing between the underlying causes of MSI in studies of etiology and prognosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18990764      PMCID: PMC2628332          DOI: 10.1158/1055-9965.EPI-08-0512

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  41 in total

1.  Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer.

Authors:  R Gryfe; H Kim; E T Hsieh; M D Aronson; E J Holowaty; S B Bull; M Redston; S Gallinger
Journal:  N Engl J Med       Date:  2000-01-13       Impact factor: 91.245

2.  Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines.

Authors:  M F Kane; M Loda; G M Gaida; J Lipman; R Mishra; H Goldman; J M Jessup; R Kolodner
Journal:  Cancer Res       Date:  1997-03-01       Impact factor: 12.701

3.  Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1.

Authors:  S N Thibodeau; A J French; J M Cunningham; D Tester; L J Burgart; P C Roche; S K McDonnell; D J Schaid; C W Vockley; V V Michels; G H Farr; M J O'Connell
Journal:  Cancer Res       Date:  1998-04-15       Impact factor: 12.701

4.  Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease.

Authors:  L A Aaltonen; R Salovaara; P Kristo; F Canzian; A Hemminki; P Peltomäki; R B Chadwick; H Kääriäinen; M Eskelinen; H Järvinen; J P Mecklin; A de la Chapelle
Journal:  N Engl J Med       Date:  1998-05-21       Impact factor: 91.245

5.  Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer.

Authors:  Wade S Samowitz; Hans Albertsen; Jennifer Herrick; Theodore R Levin; Carol Sweeney; Maureen A Murtaugh; Roger K Wolff; Martha L Slattery
Journal:  Gastroenterology       Date:  2005-09       Impact factor: 22.682

6.  Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences.

Authors:  H Kim; J Jen; B Vogelstein; S R Hamilton
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

7.  Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma.

Authors:  J G Herman; A Umar; K Polyak; J R Graff; N Ahuja; J P Issa; S Markowitz; J K Willson; S R Hamilton; K W Kinzler; M F Kane; R D Kolodner; B Vogelstein; T A Kunkel; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

8.  Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability.

Authors:  J M Cunningham; E R Christensen; D J Tester; C Y Kim; P C Roche; L J Burgart; S N Thibodeau
Journal:  Cancer Res       Date:  1998-08-01       Impact factor: 12.701

9.  Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients.

Authors:  L A Aaltonen; P Peltomäki; J P Mecklin; H Järvinen; J R Jass; J S Green; H T Lynch; P Watson; G Tallqvist; M Juhola
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

10.  Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers.

Authors:  M L Veigl; L Kasturi; J Olechnowicz; A H Ma; J D Lutterbaugh; S Periyasamy; G M Li; J Drummond; P L Modrich; W D Sedwick; S D Markowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

View more
  108 in total

1.  Annexin A10 is a marker for the serrated pathway of colorectal carcinoma.

Authors:  Sara A Sajanti; Juha P Väyrynen; Päivi Sirniö; Kai Klintrup; Jyrki Mäkelä; Anne Tuomisto; Markus J Mäkinen
Journal:  Virchows Arch       Date:  2014-11-14       Impact factor: 4.064

2.  Cancer risks for the relatives of colorectal cancer cases with a methylated MLH1 promoter region: data from the Colorectal Cancer Family Registry.

Authors:  A Joan Levine; Aung Ko Win; Daniel D Buchanan; Mark A Jenkins; John A Baron; Joanne P Young; Tiffany I Long; Daniel J Weisenberger; Peter W Laird; Rebecca L McCall; David J Duggan; Robert W Haile
Journal:  Cancer Prev Res (Phila)       Date:  2011-12-05

3.  Rapid generation of rice mutants via the dominant negative suppression of the mismatch repair protein OsPMS1.

Authors:  Jie Xu; Meiru Li; Lei Chen; Guojiang Wu; Hongqing Li
Journal:  Theor Appl Genet       Date:  2012-06-12       Impact factor: 5.699

4.  Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications.

Authors:  Frank A Sinicrope; Daniel J Sargent
Journal:  Clin Cancer Res       Date:  2012-02-02       Impact factor: 12.531

5.  Honokiol radiosensitizes colorectal cancer cells: enhanced activity in cells with mismatch repair defects.

Authors:  Zhiyun He; Dharmalingam Subramaniam; Satish Ramalingam; Animesh Dhar; Russell G Postier; Shahid Umar; Youcheng Zhang; Shrikant Anant
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-08-11       Impact factor: 4.052

Review 6.  Finding the needle in a haystack: identification of cases of Lynch syndrome with MLH1 epimutation.

Authors:  Megan P Hitchins
Journal:  Fam Cancer       Date:  2016-07       Impact factor: 2.375

7.  Differential clinicopathological features in microsatellite instability-positive colorectal cancers depending on CIMP status.

Authors:  Jeong Mo Bae; Mi Jung Kim; Jung Ho Kim; Jae Moon Koh; Nam-Yun Cho; Tae-You Kim; Gyeong Hoon Kang
Journal:  Virchows Arch       Date:  2011-04-15       Impact factor: 4.064

8.  Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.

Authors:  Daniel D Buchanan; Yen Y Tan; Michael D Walsh; Mark Clendenning; Alexander M Metcalf; Kaltin Ferguson; Sven T Arnold; Bryony A Thompson; Felicity A Lose; Michael T Parsons; Rhiannon J Walters; Sally-Ann Pearson; Margaret Cummings; Martin K Oehler; Penelope B Blomfield; Michael A Quinn; Judy A Kirk; Colin J Stewart; Andreas Obermair; Joanne P Young; Penelope M Webb; Amanda B Spurdle
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

9.  Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome.

Authors:  Brittany A L Batte; Amanda S Bruegl; Molly S Daniels; Kari L Ring; Katherine M Dempsey; Bojana Djordjevic; Rajyalakshmi Luthra; Bryan M Fellman; Karen H Lu; Russell R Broaddus
Journal:  Gynecol Oncol       Date:  2014-06-14       Impact factor: 5.482

Review 10.  Chemotherapy of MMR-deficient colorectal cancer.

Authors:  N Devaud; S Gallinger
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.